Scholars Central

Conference abstract

Relative bioavailability of Rolapitant tablets compared with Rolapitant capsules and the effect of food on Rolapitant pharmacokinetics in healthy subjects

Authors: Xiaodong Wang

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Rolapitant (VARUBI®/VARUBY®), a selective and long-acting neurokinin-1 receptor antagonist, is approved in oral tablet formulation for the prevention of delayed chemotherapy-induced nausea and vomiting in adults in the US and EU. These studies assessed the relative bioavailability of Rolapitant tablet formulations compared with Rolapitant capsules used in phase-3 studies and the effect of food on Rolapitant tablet pharmacokinetics (PK) in healthy subjects. An open-label, single-dose, parallel-group study was conducted in 84 healthy subjects to evaluate the relative bioavailability of two test formulations of Rolapitant (high shear tablets and fluid bed tablets; each 2Ã?90 mg) versus the reference capsules (4Ã?45 mg). A second openlabel, single-dose, parallel-group study was conducted in 80 healthy subjects to assess the effect of a high-fat meal on Rolapitant PK (2Ã?90 mg the intended commercial formulation of high shear tablets). Bioavailability was similar for the test tablets versus capsules. For tablets versus the capsules, the 90% confidence intervals (CI) for the geometric mean Cmax and AUC ratios were contained within the equivalence limits of 0.80 to 1.25. For the food effect assessment, the 90% CIs for the geometric mean AUC ratios (fed/fasted) were within 0.8 to 1.25. These data suggested that the bioavailability of Rolapitant following administration as 2Ã?90 mg high shear tablets and 2Ã?90 mg fluid bed tablets was comparable to that following administration of 4Ã?45 mg of the reference capsules. In addition, Rolapitant can be taken without regard to meals.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioequivalence & Bioavailability
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Xiaodong Wang”